TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39245584
Drug: Typhoid Vi
Normalized name: Typhoid Vi polysaccharide vaccine
DrugBank: Typhoid Vi polysaccharide vaccine (DB10803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Vi Polysaccharide vaccine (Typhim Vi)
Study: 39245937
Drug: CABA-201 (fully
Approvals — FDA: no, EMA: no, PMDA: no
Description: CABA-201 (fully human, 4-1BBz anti-CD19-CAR T cell therapy)
Study: 39246736
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for opioid use disorder
Study: 39246736
Drug: Mental health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental health medication
Study: 39246931
Drug: 5% lifitegrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lifitegrast ophthalmic solution
Study: 39247686
Drug: Bamlanivimab 700
Normalized name: bamlanivimab 700 MG in 20 mL Injection (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamlanivimab 700 mg mAb therapy
Study: 39248107
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg) and Minocycline (100 mg) - dual therapy for 12 weeks
Study: 39248107
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg) or Lovastatin (40 mg) - monotherapy for 8 weeks
Study: 39248170
Drug: Guideline-recommended therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-recommended therapy initiated if AF is detected.
Study: 39249590
Drug: Magaldrate (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magaldrate (800 mg) with sodium alginate (500 mg), sodium bicarbonate (267 mg), and simethicone (120 mg)
Study: 39249590
Drug: Magaldrate (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magaldrate (800 mg)
Study: 39249605
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with cisplatin-based chemoradiotherapy and pembrolizumab (200 mg, IV every 3 weeks for 18 cycles)
Study: 39249605
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy with cisplatin-based chemoradiotherapy and pembrolizumab
Study: 39250131
Drug: Nurse-supported self-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-supported self-directed cognitive behavioral therapy for insomnia (CBTi) with six weekly phone calls and assigned treatment manual readings.
Study: 39250131
Drug: Nurse-supported self-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-supported self-directed cognitive behavioral therapy for insomnia (CBTi)
Study: 39250326
Drug: GSK3858279 (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3858279 (monoclonal antibody against CCL17)
Study: 39250515
Drug: Resmetirom 100
Normalized name: resmetirom 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resmetirom 100 mg
Study: 39250515
Drug: Resmetirom (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resmetirom (80 mg and 100 mg pooled)
Study: 39250646
Drug: Peer delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer delivery of oral-fluid HIVST, STISS, and PrEP refills
Study: 39250708
Drug: Subcutaneous decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous decitabine at 0.3 mg/kg per day for 10 days
Study: 39250887
Drug: Normobaric hyperoxia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normobaric hyperoxia (NBO) combined with endovascular treatment (EVT), administered with mask oxygen therapy of 10 L/min.
Study: 39250887
Drug: Sham NBO
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham NBO (1 L/min) combined with endovascular treatment (EVT).
Study: 39250922
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor plus standard-of-care
Study: 39251366
Drug: TICK-B (colouring
Approvals — FDA: no, EMA: no, PMDA: no
Description: TICK-B (colouring book) and TKTX cream (topical anaesthetic)
Study: 39251366
Drug: TKTX cream
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TKTX cream (topical anaesthetic)
Study: 39251447
Drug: Family Meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family Meals on Prescription (FMP) combined with lifestyle treatment
Study: 39251447
Drug: Lifestyle treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle treatment alone (Control)
Study: 39251616
Drug: Lower volume
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower volume administration and higher vasoactive support (postoperative hemodynamic management)
Study: 39252657
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate (225 mg twice daily)
Study: 39252657
Drug: Oral testosterone
Normalized name: testosterone Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral testosterone undecanoate
Study: 39252657
Drug: 1.62% topical
Normalized name: Testosterone 1.62% Topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.62% topical testosterone gel
Study: 39252865
Drug: Adebrelimab (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab (20 mg/kg, D1, Q3W) plus chemotherapy (EP/EC) followed by sequential thoracic radiotherapy (TRT)
Study: 39252867
Drug: Hexasodium fytate
Normalized name: Hexasodium fytate
DrugBank: Hexasodium phytate (DB18232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexasodium fytate 7 mg/kg
Study: 39253004
Drug: Attachment-Based Compassion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attachment-Based Compassion Therapy
Study: 39253004
Drug: Usual treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual treatments (workshops)
Study: 39253025
Drug: Collaborative Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative Care (CC) intervention, TBI Care, with weekly assessments and an average of 11 out of 12 sessions with a care manager (CM).
Study: 39253025
Drug: Collaborative Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative Care (CC) intervention, TBI Care.
Study: 39253712
Drug: hs-cTnT >9.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-cTnT >9.6 ng/L (highest category)
Study: 39253713
Drug: RAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitors prescribed in patients with periprocedural myocardial injury (197 patients, 70%)
Study: 39253713
Drug: RAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitors prescribed in patients without periprocedural myocardial injury (1,251 patients, 71.2%)
Study: 39254129
Drug: Break Wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Break Wave lithotripsy (BWL) device, single treatment of 30 minutes at peak negative pressure of 4.5 to 8 MPa.
Study: 39254129
Drug: Break Wave
Normalized name: ELECTRODE GEL,H-WAVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Break Wave lithotripsy (BWL) device, after optimal therapy settings determined.
Study: 39254466
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy for 24 hours per day
Study: 39254466
Drug: Long-term oxygen
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oxygen therapy for 15 hours per day
Study: 39254890
Drug: Ritlecitinib 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 30 mg or 50 mg once daily (with or without an initial 4-week 200-mg daily loading dose)
Study: 39255444
Drug: B7-H3 chimeric
Normalized name: allogeneic T cells genetically modified to express anti-B7-H3 chimeric antigen receptor (CAR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B7-H3 chimeric antigen receptor (CAR) T cells at dose level 1 (DL1) 0.5 × 10^6 cells
Study: 39255444
Drug: B7-H3 chimeric
Normalized name: allogeneic T cells genetically modified to express anti-B7-H3 chimeric antigen receptor (CAR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: B7-H3 chimeric antigen receptor (CAR) T cells
Study: 39255534
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously once every 21 days
Study: 39255587
Drug: mRNA-1345 100
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1345 100 μg
Study: 39255991
Drug: MK-5475 32
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5475 32 µg
Study: 39255991
Drug: MK-5475 100
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5475 100 µg
Study: 39255991
Drug: MK-5475 380
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5475 380 µg
Study: 39255990
Drug: BI 1291583
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1291583 5 mg
Study: 39255990
Drug: BI 1291583
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1291583 2.5 mg
Study: 39255990
Drug: BI 1291583
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1291583 1 mg
Study: 39256281
Drug: Metallic taste
Normalized name: Aluminum metal
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metallic taste (MT) experienced by patients during treatment
Study: 39256291
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg/tramadol 50 mg (QD for 7 days)
Study: 39256291
Drug: Paracetamol 975
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 975 mg/tramadol 112.5 mg (TID for 7 days)
Study: 39256350
Drug: AAV8-RLBP1 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AAV8-RLBP1 gene therapy
Study: 39256835
Drug: FFA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFA levels ≥ 580 µmol/L
Study: 39256835
Drug: FFA levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFA levels < 310 µmol/L
Study: 39258838
Drug: Liraglutide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (3.0 mg once daily)
Study: 39258976
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab vedotin administered after chemotherapy and immunotherapy
Study: 39259542
Drug: Open-label placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label placebo (OLP) - 1-time subcutaneous lumbar saline injection presented as placebo
Study: 39259546
Drug: Written health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written health education materials (monthly)
Study: 39259550
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy for inpatients (up to 4 individual sessions)
Study: 39259550
Drug: Brief cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief cognitive behavioral therapy for inpatients
Study: 39259562
Drug: Brigimadlin (BI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigimadlin (BI 907828), oral administration, intermittent dosing schedule
Study: 39259562
Drug: Brigimadlin (BI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brigimadlin (BI 907828), oral administration
Study: 39259959
Drug: VR motor-cognitive
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR motor-cognitive training (VRMCT) - 16 one-hour training sessions delivered twice per week for 8 weeks.
Study: 39260076
Drug: suvorexant (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: suvorexant (10-20 mg)
Study: 39260392
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (laxative regimens)
Study: 39260392
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (colostomy, segmental resection, hemicolectomy, subtotal colectomy)
Study: 39260540
Drug: Gefapixant (45-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefapixant (45-mg twice daily)
Study: 39260785
Drug: Renin Angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin Angiotensin system inhibitors (RASi) therapy
Study: 39260856
Drug: Second TNF
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Second TNF blocker
Study: 39261482
Drug: mRNA-1273 third
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 third dose
Study: 39261786
Drug: Healthy diet
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy diet combined with mindfulness cognitive therapy (educational group-based sessions on Mediterranean-type diet and mindfulness principles)
Study: 39261815
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training (group and individual) for four months, including pelvic floor muscle training (PFMT) recommended daily
Study: 39261900
Drug: 6-monthly monitoring
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly monitoring of serum neurofilament light chain (sNfL) in addition to usual care (group A)
Study: 39261900
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care with 6- or 12-monthly visits (group B)
Study: 39261953
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy to address maladaptive thought patterns and behaviors around social connection
Study: 39262903
Drug: Shi's manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shi's manual therapy (SMT)
Study: 39262903
Drug: Merislon (Betahistine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merislon (Betahistine Mesilate Tablets)
Study: 39263280
Drug: Intranasal esketamine
Normalized name: esketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intranasal esketamine 2 mg/kg (Group K)
Study: 39263280
Drug: Esketamine 1
Normalized name: esketamine 140 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine 1 mg/kg and dexmedetomidine 1 µg/kg (Group KD1)
Study: 39263280
Drug: Esketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine 0.5 mg/kg and dexmedetomidine 2 µg/kg (Group KD2)
Study: 39263597
Drug: Twice-nightly immediate-release
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-nightly immediate-release (IR) oxybate
Study: 39263892
Drug: Pressurized intraperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) with nab-paclitaxel plus systemic gemcitabine, cisplatin, and durvalumab (gem/cis/durva)
Study: 39263892
Drug: Systemic treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic treatment comprising gemcitabine, cisplatin, and durvalumab (gem/cis/durva)
Study: 39264108
Drug: eHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: eHealth intervention group (12 interactive modules on PA, DB, and sleep delivered weekly)
Study: 39264108
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly brochures on PA, DB, and sleep recommendations)
Study: 39264438
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 70 µg/day (2800 IU)
Study: 39264438
Drug: Antithyroid drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drugs (ATD)
Study: 39264503
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of atorvastatin
Study: 39264535
Drug: Glenohumeral hydrodistension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glenohumeral hydrodistension combined with bursal injection
Study: 39264599
Drug: MYL-1701P (0.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MYL-1701P (0.5-mg vial) every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52
Study: 39264599
Drug: Reference aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Reference aflibercept every 4 weeks for 5 consecutive intravitreal injections, followed by every 8 weeks through week 52
Study: 39761483
Drug: Datopotamab deruxtecan
Normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Datopotamab deruxtecan (Dato-DXd) 6 mg/kg once every 3 weeks
Study: 39265161
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine diagnostic tools
Study: 39265161
Drug: Health Evaluation
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health Evaluation Questionnaire, Physical Activity Questionnaire, sugar intake assessment, Constitution in Chinese Medicine Questionnaire, radial pulse diagnosis, and tongue diagnosis
Study: 39265466
Drug: Paclitaxel and
Normalized name: paclitaxel and encequidar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel and Carboplatin (PC) - 6 cycles of P 175 mg/m2 and C AUC=6 IV every 3 weeks
Study: 39265466
Drug: Bleomycin, Etoposide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin, Etoposide, and Cisplatin (BEP) - 4 cycles of B 20 units/m2 IV push day 1, E 75 mg/m2 IV days 1-5, and Cisplatin 20 mg/m2 IV days 1-5 every 3 weeks
Study: 39265579
Drug: Trastuzumab deruxtecan
Normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab deruxtecan (T-DXd) 5.4 mg/kg intravenously every 21 days until disease progression or unacceptable toxicity.
Study: 39265613
Drug: fedratinib 400
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: fedratinib 400 mg per day
Study: 39265613
Drug: best available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: best available therapy (BAT)
Study: 39266309
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg QD orally for 3 days before surgery and 0.5 mg QOD for 10 days after surgery)
Study: 39266309
Drug: Placebo (starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (starch tablets for the same time and dosage)
Study: 39266308
Drug: Intranodal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranodal administration of tolDCs loaded with heat shock protein 70-derived peptide mB29a, two intranodal injections of 5×10 (dosage not fully specified)
Study: 39266619
Drug: DP303c administered
Normalized name: ADC DP303c
DrugBank: DP-303c (DB17212)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP303c administered intravenously every 3 weeks at doses of 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 3.0 mg/kg, and 4.0 mg/kg.
Study: 39266747
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination of HIV-1 broadly neutralizing antibodies (bNAbs)
Study: 39266747
Drug: Monotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy or cocktail of two antibodies
Study: 39266862
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with Chinese herbal medicine (chemo+CHM)
Study: 39266862
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with placebo (chemo+placebo)
Study: 39266938
Drug: Online biopsychobehavioral
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online biopsychobehavioral rehabilitation study including phosphodiesterase-5 inhibitors, sexual aids, pelvic floor exercise regimen, video, guide to good gay sex, and coaching.
Study: 39266961
Drug: Escalating doses
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating doses of CBD (5 mg CBD/kg/day to 30 mg CBD/kg/day, escalated every two weeks in increments of 5 mg CBD/kg/day)
Study: 39266985
Drug: Root Canal
Normalized name: Canal + Gel 10% for Root Canal Preparation Dental Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Root Canal Treatment (RCT)
Study: 39267085
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups receive concurrent chemotherapy with capecitabine and consolidation chemotherapy of either two cycles of CAPEOX or three cycles of FOLFOX between radiotherapy and surgery
Study: 39267574
Drug: Inosine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine (0.2 g, three times/day) + PD-1/PD-L1 inhibitor
Study: 39267574
Drug: Non-inosine (PD-1/PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-inosine (PD-1/PD-L1 inhibitor ± targeted ± chemotherapy)
Study: 39267685
Drug: Personalized mRNA
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-1273 Injectable Suspension [Spikevax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized mRNA vaccine (1 mg every 3 weeks for 4 cycles) combined with PD-1 inhibitor therapy.
Study: 39267685
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 inhibitor therapy (single dose 8 weeks after the 4th cycle).
Study: 39268119
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (Venturi mask or nasal goggles) after early extubation for 48 hours
Study: 39268699
Drug: Single 300-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 300-mg dose of bepirovirsen in participants with hepatic impairment (HI)
Study: 39268857
Drug: Durvalumab (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1500 mg)